Effect of statin use on outcome of symptomatic cholelithiasis: a case-control study by Jukka Pulkkinen et al.
Pulkkinen et al. BMC Gastroenterology 2014, 14:119
http://www.biomedcentral.com/1471-230X/14/119RESEARCH ARTICLE Open AccessEffect of statin use on outcome of symptomatic
cholelithiasis: a case-control study
Jukka Pulkkinen1,2*, Matti Eskelinen1,2, Vesa Kiviniemi3, Tuukka Kotilainen2, Markus Pöyhönen2, Lasse Kilpeläinen2,
Pirjo Käkelä1,2, Helena Kastarinen3 and Hannu Paajanen1,2Abstract
Background: Statins can modify bile cholesterol and, thus, the formation of gallstones. We examined whether
statin use also modifies the severity of symptomatic gallstone disease and its treatment.
Methods: A total of 1,140 consecutive patients with symptomatic gallstone disease were recruited during
2008-2010 at Kuopio university hospital, Finland. Case-control analysis matched the patients using (n = 272) or
not using (n = 272) statins by age and sex. The baseline characteristics of the patients, need and type of surgical
treatment, duration of operation, perioperative bleeding, postoperative complications and overall mortality rate
were compared statistically between the study groups.
Results: Morbidity and subsequent polypharmacy occurred more frequently among the patients with statins
compared to the patients without statins. There were no significant differences between the statin users and
non-users regarding surgical treatment (open vs. laparoscopic cholecystectomy). The mean operation time for
laparoscopic cholecystectomy was 10% shorter for the patients with statin use than for the patients without.
In addition, there was a non-significant tendency for statin users to bleed less during laparoscopic operations
than the non-users. There were no differences in other procedure-related parameters (e.g., operation urgency,
conversions, choledochotomies, complications and mortality) in patients with or without statins.
Conclusions: Compared to no treatment, statin treatment was associated with a shorter operation time for
laparoscopy cholecystectomy. Other surgical outcome parameters were similar in patients with or without statins,
although statin users had more polypharmacy and circulatory illnesses than non-users.
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Gallstone disease and cholesterol-lowering statin medica-
tions are common in Western countries, and they have
a high economic impact [1]. Symptomatic gallstones
are one of the leading causes of inpatient admissions in
general surgery [2]. The prevalence of gallstone disease
is increasing because of worldwide epidemics of obesity,
insulin resistance and aging. In Western populations,
the majority of gallstones formed in the gallbladder
consist mainly of cholesterol, as they are formed from
cholesterol-supersaturated bile [3]. Cholesterol gallstones* Correspondence: j.pu@dnainternet.net
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unless otherwise stated.account for 80-95% of the gallstones found during chole-
cystectomy [4,5].
Hypercholesterolemia is an important risk factor for
atherosclerosis, which has been the most common cause
of death in developed countries. Statins are used to treat
dyslipidemia, which prevents cardiovascular or cerebro-
vascular events. Statins are among the most widely used
medications in the Western world [6,7]. As in other
Western societies, statin use in Finland has increased
exponentially: There has been an 11-fold increase in
statin use between 1995 and 2005 [8]. According to the
reimbursement register data of the Social Insurance
Institute of Finland (population 5.2 million), approximately
660,000 individuals purchased statins in 2012, which is
12% of population.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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gallstone disease is still more or less conflicting, although
several studies have reported a significant reduction in the
incidence of symptomatic gallstones disease in patients
using statin therapy [9]. The most consistent evidence
is that bile is desaturated of cholesterol after the long-
term administration of statins [10,11]. These observations
suggest that statins may reduce the size of cholesterol
particles and, subsequently, prohibit gallstone formation
and reduce the size of gallstones; therefore, they may also
affect the course of symptomatic gallstone disease. The
effect of statin therapy on the course and outcome of
cholecystectomy is unknown.
We conducted a case control study to assess the influ-
ence of statins on complicated gallstone disease. Based on
the effect of statins on gallstone formation, we hypo-
thesized that statin use would be associated with less
severe acute gallbladder inflammation, fewer stones in the
common bile duct and, furthermore, fewer complications.
Methods
A total of 1,140 consecutive patients with symptomatic
gallstones were admitted to Kuopio University Hospital,
Finland, from 2008-2010. The hospital serves an area of
243,000 inhabitants. A total of 272 of 1,140 patients with
symptomatic cholelithiasis underwent statin therapy. The
age- and sex-matched controls (n = 272) were randomly
selected from the cohort of patients without statin
therapy. Patient data were obtained from the hospital
records using the following discharge diagnoses (ICD 10):
K80 (cholelithiasis), K81 (cholecystitis), K82 (other disease
of gallbladder) or K83 (other diseases of biliary tract).
The imaging study results (i.e., computed tomography,
abdominal ultrasound, magnetic resonance cholangiog-
raphy) were analyzed. Additional work-ups included a
detailed clinical history with records of recent infectious
diseases, abdominal traumas, surgery, and endoscopic
retrograde cholangiopancreatography (ERCP), as well
as data concerning comorbidities and medicine use on
arrival. The laboratory data included serum calcium, lipids,
liver enzymes and C-reactive protein measurements. The
duration of hospital stay, need for intensive care treat-
ment and one-month hospital mortality (2008-2010) were
recorded. Data concerning the treatment type (e.g.,
conservative, laparoscopic, open surgery, conversions,
cholecystostomy, and choledochotomies), surgical dura-
tions, elective vs. emergency operations, complications,
bleeding and number of re-operations were collected
from the patients records.
Surgery was performed in both study groups using
the same operative principles and by the same group of
surgeons. There were no between-group differences in
the preoperative or perioperative treatments or proce-
dures. Emergency cholecystectomy was performed ifultrasonography or clinical examination and laboratory
parameters revealed signs of cholecystitis in and if the
patient was suitable for operation, according to the
American Society of Anesthesiologists physical status
classification system. If possible, perioperative cholangi-
ography was always performed in acute cholecystitis.
Cholecystectomy was primarily performed laparoscopically.
In patients with very old age and severe comorbidities,
percutaneous cholecystostomy was performed. In patients
with long histories of cholecystitis symptoms, the treat-
ment was first conservative, and elective laparoscopy was
performed later. According to the Finnish legislation,
no ethical assessment or approval is mandatory for a
register-based study. As this is a retrospective register
study, informed consent from the patients was not needed.
Data were analyzed using IBM SPSS (Statistical Package
for the Social Sciences) Statistics 21.0 (IBM Corp. Released
2012. IBM SPSS Statistics for Windows, Version 21.0.
Armonk, NY: IBM Corp. USA), and the statistical analyses
were performed using independent samples t-tests, Mann-
Whitney U-tests and χ2 tests, depending on the distribution
of the outcome and distributional assumptions. Adjusted
analyses of outcomes were not conducted because of the
relatively small number of events in various outcomes
of interest. P values less than 0.05 were considered to
be statistically significant.Results
A total of 1140 admissions of the patients with sympto-
matic cholelithiasis were recorded at our hospital between
2008 and 2010. There were 715 females and 425 males
(63% and 37%, respectively). Some 272 patients used statins
(24% of the whole study population), 132 females and
140 males (17.6% and 32.9%, respectively), (Table 1). The
patients using statin therapy were, on average, older, had a
greater incidence of type II diabetes and cardiovascular
diseases and were more frequently male than the patients
without statin therapy (data not shown).Statin users vs. their matched controls
In the case control comparison, hypertension and cardiac
diseases were observed more frequently among the statin
users compared with the non-users (Table 1). On the con-
trary, the prevalence of diabetes, neurological, psychiatric,
and pulmonary diseases, as well as malignancy, were
similar in both study groups. The mean BMI was simi-
lar between the groups. In the statin group, simvastatin
constituted 73% and atorvastatin 13% of all statins
(Table 1).
We also calculated the number of regularly used drugs
in both groups. Polypharmacy (>4 medicines) was observed
in more than 80% of the patients in the statin group and
in 48% of the patients in the no-statin group (p < 0.001).
Table 1 Demographic data of statin users (n = 272) and non-statin users (n = 272) patients with gallstones
Statin users (n = 272) No statin (n = 272) P-value
Females/males 132/140 (48%/52%) 132/140 (48%/52%) 1.000
Age (years) 69 ± 11 (36-93) 69 ± 11 (36-93) 0.786










Hypertension 161 (59%) 115 (42%) < 0.001
Diabetes 48(18%) 38 (14%) 0.290
Coronary artery disease/
Coronary heart failure/
Valvular 151 (56%) 71 (26%) < 0.001
Neurological 50 (18%) 48 (18%) 0.456
Psychiatric 16 (6%) 22 (8%) 0.401
Pulmonary 32 (12%) 37 (14%) 0.303
Rheumatoid 12 (4%) 12 (4%) 1.000
Malignancy 26 (10%) 33 (12%) 0.408
Number of medication
No 0 75 (28%)
1-3 drug 44 (16%) 88 (32%)
> 4 drugs 228 (84%) 109 (40%)
1Means combination of statin with other cholesterol-lowering drugs (fenofibrate, ezetimibe).
Values are presented as number (percentage) or mean (SD, min-max), as appropriate.
Table 2 Laboratory data of study groups
Statin use (n = 272) No statin (n = 272) p-value
P-Amyl U/l 76 (166) 113 (478) 0.873
P-Afos U/l 134 (148) 131 (132) 0.924
P-Bil umol/l 24 (31) 30 (42) 0.171
ALAT U/l 89 (141) 108 (181) 0.639
fP-Kol-LDL mmol/l 2.2 (1.0) 2.4 (1.0) 0.622
fP-TRIG mmol/l 1.6 (0.9) 1.5 (0.8) 0.805
CRP mg/l 112 (100) 113 (111) 0.604
Values are expressed as mean (SD).
p-values are indicated using the Mann-Whitney U-test.
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any medicines upon admission (data not shown).
We did not observe any statistically significant between-
group differences in any of the assessed laboratory para-
meters, including LDL cholesterol. The mean C-reactive
protein concentration was 112 mg/l in the statin group
and 113 mg/l in the no-statin group (Table 2).
Approximately 27% of patients in the statin group and
25% of patients in the non-statin group were treated
conservatively (Table 3). Approximately 68% of all opera-
tions were elective, and 32% were emergency procedures.
Three quarters of the operations were started with
laparoscopy. The mean conversion rate to open surgery
was 13%. One patient in the non-statin group was re-
operated two times: first because of bile leak and again
because of abscesses. We found no significant differences
between the statin users and non-users regarding the
treatment types (elective/emergency, laparoscopic/open)
or in the number of conversions or ERCP procedures(Table 3). Furthermore, there were no significant diffe-
rences in the rate of complications, need for intensive care
treatment or hospital mortality. Interestingly, the hospital
mortality rates were similar among the statin users and
the non-users (Table 3).
Table 3 Treatment and outcome of patients with cholelithiasis
Statin use (n = 272) No statin (n = 272) p-value
Overall mortality 12 (4%) 19 (7%) 0.195
ICU treatment (N patients) 6 (2%) 3 (1%) 0.348
Mean hospital stay, days 4.3 ± 9.9 3.9 ± 4.7 0.7301
Treatment type
Conservative/Surgical 73/199 (27/73%) 68/204 (25/75%) 0.625
Elective/emergency operation 138/61 (69/31%) 136/68 (67/33%) 0.769
Laparoscopic 131 (65%) 130 (64%) 0.659
Open surgery 47 (24%) 46 (23%) 0.799
Conversion 13 (7%) 17 (8%) 0.491
Cholecystostoma 8 (4%) 11 (5%) 0.516
Reoperations 6 (3.0%) 3 (1.5%) 0.211
Choledochotomy 13 (7%) 20 (10%) 0.197
Choledocholithiasis 9 (5%) 20 (10%) 0.104
Complications (operated) 27 (13.6%) 32 (15.7%) 0.733
Urological 5 (2.5%) 7 (3.4%)
Peritonitis 3 (1.5%) 3 (1.5%)
Bleeding 4 (2.0%) 3 (1.5%)
Bile leak 3 (1.5%) 1 (0.5%)
Other abscess 1 (0.5%) 1 (0.5%)
Heart complication 1 (0.5%) 1 (0.5%)
Lung complication 1 (0.5%) 0
Other 9 (4.5%) 16 (7.8%)
ERCP (all) 31 (11%) 34 (13%) 0.595
Values are shown as number (percentage) or mean (SD) unless otherwise indicated.
1Indicates the Mann-Whitney U-test.
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conducted as an emergency procedure compared with
laparoscopic surgery (Table 4).
Interestingly, the mean time for laparoscopic operations
was 9.4 minutes shorter in the statin group compared
with the control group (p = 0.042). In addition, the time
needed for open surgery was shorter in the statin group
compared with the non-statin group, although this
difference was not statistically significant. Likewise, there
was a non-significant trend of increased bleeding among
the non-statin group.
Logistic regression analysis was used to adjust for
age, gender and outcomes. The results did not differ
from the unadjusted results presented in Table 4. Over-
all, the number of patients having outcomes was too
small to conduct more extensive adjusted analyses (i.e.,
adjusting for co-morbidities). All open and converted
patients remained, on average, three days longer in the
hospital than the laparoscopic patients (mean 5.8 ± 5.0
and 2.6 ± 9.9, respectively, P < 0.001). There were no
between-group differences regarding the hospitalization
time (Table 4).Discussion
The main finding of the present study was that the
patients using statins did not have worse outcomes after
cholecystectomy than the non-users, although the statin
users were older, had polypharmacy and demonstrated
more comorbidities than the non-users. Statin therapy
was also associated with a shorter laparoscopic operation
time. There was also a trend of other benefits from
statin use for surgical outcomes, such as less bleeding.
These findings are of clinical importance, as one would
anticipate that statin users would have more post-
surgical complications than non-users. A well-conducted
prospective randomized study to show the possible
benefits of statins in cholecystectomy is warranted.
The risk of developing symptoms or complications
related to gallstones is approximately 1–4% per year
[12,13]. The known risk factors for gallstones are female
gender, increasing age, obesity, metabolic syndrome,
rapid weight loss and gallbladder stasis [14,15]. The
most important complications of the gallstone disease
are biliary pancreatitis, cholecystitis and cholangitis.
Festi et al. showed that during follow-up, approximately
Table 4 Outcome of cholelithiasis in open and laparoscopic surgery
Statin use (n = 272) No statin (n = 272) p-value
Surgery (laparoscopic and open) N = 178 N = 176
Laparoscopic 131 (74%) 130 (74%)
Elective/Emergency 116/15 (89%/11%) 109/21 (84%/16%) 0.271
Mean operation time 71.4 ± 31.5 80.81 ± 39.2 0.042
Mean bleeding 20.8 ± 79.2 32.6 ± 88.1 0.070
Bleeding over 100 ml 7 (5%) 14 (11%) 0.099
Mean hospital stay, days 3.1 ± 13.5 2.2 ± 3.4 0.6001
Proportion of patients
with more than 3 hospital days 42 (32%) 46 (35%) 0.602
Proportion of patients
with more than 5 hospital days 13 (10%) 10 (8%) 0.525
Open surgery (conversions excl.) 47 (26%) 46 (26%)
Elective/Emergency 14/33 (30%/70%) 15/31 (33%/67%) 0.769
Mean operation time 92.9 ± 38.1 104.8 ± 49.2 0.248
Mean bleeding 208.2 ± 275.1 229.5 ± 276.0 0.332
Bleeding over 100 ml 20 (43%) 18 (39%) 0.960
Mean hospital stay 6.1 ± 4.2 6.4 ± 6.5 0.788
Proportion of patients with more than 5 hospital days 28 (60%) 25 (54%) 0.611
Data are shown as mean (SD) or (percentage) unless otherwise indicated.
1Indicates the Mann-Whitney U-test.
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symptoms, and 10% develop severe symptoms leading to
cholecystectomy [16]. The development of the sympto-
matic gallstones is associated with obesity and alcohol use,
likely because of their effects on serum lipids [17]. It is
presently unknown whether statin therapy would trans-
form asymptomatic cholelithiasis to symptomatic.
The use of statins and other lipid-lowering drugs has
been greatly increasing in Finland in recent years [8].
This increase has occurred particularly among elderly
patients with hypercholesterolemia [18]. Prior to beginning
our study, we anticipated that statin users would have
less severe acute gallbladder inflammation, fewer stones
in the common bile duct and more frequent laparoscopic
cholecystectomy than non-users; this hypothesis proved
wrong. Statins reduce the bile cholesterol content, which
may theoretically reduce the risk of developing micro-
gallstones or sludge. In the present study, the 1-year inci-
dence of symptomatic cholelithiasis was approximately
0.22% among statin users and 0.14% among non-statin
users (these calculations are based on reimbursement
register data, data not shown).
Bodmer et al. performed a case control study using a
UK-based database of approximately 5 million patients
to investigate statins and the reduced risk of gallstone
disease. In this large observational study, a lower incidence
of cholecystectomy was noted in patients taking statins[3]. In addition, Tsai et al. performed a large retrospective
cohort study among 2479 American women who had
histories of gallstones. The authors found that statin use
was associated with a reduced risk of cholecystectomy
[10]. Smith et al. observed that simvastatin (20 mg/day)
decreased plasma and biliary cholesterol levels by redu-
cing cholesterol synthesis after 3 weeks of medication
[19]. A long-term study in prairie dogs found that
lovastatin alters biliary lipid composition and dissolves
gallstones [20]. However, most human studies did not
find that statin monotherapy would lead to the complete
dissolution of gallstones [11]. In accordance with this
finding, the need of surgery of any type or the chole-
lithiasis outcomes did not differ between the statin and
non-statin groups, which contrasted with some previous
studies. In a Taiwanese study, the investigators did not
find a beneficial association between statin use and
gallstone disease [21]. However, in East Asia, there is a
lower prevalence of gallstones, and the stones primarily
have a brown pigment, which indicates that they are
comprised mainly of calcium [1].
Statins were not associated with a lower total serum
bilirubin level in our study. In 2011, Ong et al. published
a contrasting finding. They investigated whether statins
in routine use increase the total bilirubin levels in sub-
jects at high cardiovascular risk; but unexpectedly, the
authors found that statin use was associated with lower
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be explained, at least partially, by the effect of statins on
glycemia and LDL cholesterol [22].
The clinical outcomes did not differ significantly between
the study groups, except for the laparoscopic operation
time. A shorter laparoscopic operation time was un-
expected, as these patients more often have heart disease
or hypertension. Conversely, the patients with cardiac
disorders used more medications, thereby affecting the
bleeding cascade, which would predispose them to bleed-
ing complications. On average, more bleeding was ob-
served among non-users compared with users during
laparoscopic operations, but the difference remained
statistically insignificant with a p value of 0.07. However,
this finding is in line with the shorter operation time
among statin users. Possible mechanisms behind these
findings may include smaller size of cholesterol particles
and gallstones. More research with larger sample sizes is
warranted to confirm these findings. The two-year morta-
lity rate (the study time mortality) was also similar among
the statin users and non-users. Four patients died in
the hospital. Longer observation time mortality was not
studied in this study.
The mechanism by which statins might shorten the
operation time or diminish bleeding remains unknown
and requires further study. There were no differences in
the perioperative procedures between the groups, and
the same surgical team was in charge of their treatment.
There is evidence that statins might have relevant anti-
inflammatory effects independent of their lipid lowering
ability [23].
The factors that contribute to supersaturating choles-
terol in bile and to the formation of cholesterol gallstones
are multifactor. Major sources of cholesterol for biliary
secretion are the intestine, liver hepatocytes and circula-
ting lipoproteins. Gallbladder hypomotility, destabilization
of bile by kinetic protein factors, abnormal mucins and
genetic factors also play roles in cholesterol gallstone
disease [24]. Many other factors are associated with
cholesterol gallstones formation, such as dietary and life
style factors and associated conditions (obesity, estrogen
therapy, metabolic syndrome, etc.).
Our study had some limitations. Because this study was a
retrospective analysis, we could not determine whether the
gallstone formation developed before the statin medication
was administered. Gallstone formation occurs over a long
time period. Furthermore, we do not have accurate data on
the patients’ adherence to statin use nor on the duration of
the statin treatment in individual patients. Most gallstones
are asymptomatic, and the patient does not require a
cholecystectomy or hospital admission [25]. In this study,
all patients were hospitalized because they had gallstone-
related symptoms or complications. We do not have data
from the patients with asymptomatic gallstone disease.Conclusion
The patients using statins did not have worse outcomes
after cholecystectomy than the non-users.
We found that statins might shorten laparoscopic sur-
gery time in patients who have symptomatic cholelithiasis.
Statin treatment may also be associated with less bleeding
during laparoscopic operations. The beneficial effects of
statins were observed, although statin use was associated
with more comorbidities and patient polypharmacy. A
prospective randomized study is needed to show the
protective effects of statins on gallbladder surgery.
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